CGEM Cullinan Therapeutics (CGEM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001789972
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
117
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $180.6K priced
What the filings say about CGEM
Insiders, 180 days
-$1.0M net sold
1 seller · 20% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$764.7K
2 notices
Cullinan Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cullinan Therapeutics, Inc. insiders sold a net $1.0M of stock across 204 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 50 earlier Form 4 trades (code P or S) here by this insider (50 sales), the last on Aug 13, 2026.
- The trade is 5.0% of the 158,844 shares held after it.
- No other insider sold within 30 days.
- 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Michaelson Jennifer sold about $172.6K of CGEM under a 10b5-1 plan on Sep 8, 2026; 117 funds added in the latest 13F quarter.Context
- 49 earlier Form 4 trades (code P or S) here by this insider (49 sales), the last on Jul 6, 2026.
- The trade is 18.4% of the 162,844 shares held after it.
- No other insider sold within 30 days.
- 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Michaelson Jennifer sold about $607.8K of CGEM on Aug 13, 2026, the largest insider sale at the company since 2024; 117 funds added in the latest 13F quarter.Context
- 48 earlier Form 4 trades (code P or S) here by this insider (48 sales), the last on May 5, 2026.
- The trade is 4.9% of the 162,844 shares held after it.
- No other insider sold within 30 days.
- 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Michaelson Jennifer sold about $142.6K of CGEM on Jul 6, 2026; 117 funds added in the latest 13F quarter.Context
- 46 earlier Form 4 trades (code P or S) here by this insider (46 sales), the last on Mar 5, 2026.
- The trade is 0.1% of the 166,844 shares held after it.
- No other insider sold within 30 days.
- 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Michaelson Jennifer sold about $3.1K of CGEM on May 5, 2026; 117 funds added in the latest 13F quarter.Context
- 46 earlier Form 4 trades (code P or S) here by this insider (46 sales), the last on Mar 5, 2026.
- The trade is 4.7% of the 167,044 shares held after it.
- No other insider sold within 30 days.
- 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Michaelson Jennifer sold about $113.9K of CGEM on May 5, 2026; 117 funds added in the latest 13F quarter.204 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.0M over 180 days
-$780.4K over 90 days
below 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
117 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.9% of the float short (float per yahoo 2026-10-26) · 5.1 days to cover · settled 2026-09-30
more than 78% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CGEM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+77.0%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CGEM: institutional holders (13F)
13F holdings, latest reported quarter
17,927,000 sh
$326.5M
9,731,341 sh
$177.2M
5,750,683 sh
$104.7M
5,232,766 sh
$95.3M
3,668,627 sh
$66.8M
Congress trades in CGEM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CGEM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JENNIFER MICHAELSON
Filed 2026-09-08
$176.7K
JENNIFER MICHAELSON
Filed 2026-08-13
$588.0K
JENNIFER MICHAELSON
Filed 2026-07-06
$141.0K
CGEM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$374.3K position · as of 2026-07-31
0.8%
AlphaCentric Life Sciences and Healthcare Fund
$372.0K position · as of 2026-06-30
0.8%
Tema Oncology ETF
$1.0M position · as of 2026-05-31
0.6%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.7M position · as of 2026-05-31
0.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$43.3M position · as of 2026-06-30
0.4%
PROFUND VP BIOTECHNOLOGY
$192.0K position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 9 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
9
Phase 1
7 active
3
Multi-phase
2 active
What changed recently
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymp
2026-10-23 · Active Not Recruiting → Terminated · Strategic business decision
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.1M
$2.3M
$2.2M
-2%
n/a
2024
$7.7M
$8.9M
$3.8M
+15%
n/a
2023
$4.0M
-$3.1M
$2.3M
-3%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.0M sold by insiders over 180 days, 117 funds added last quarter, $764.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CGEM financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2022-01-01 to 2022-12-31
Revenue, TTM CGEM
| FY Dec 2025 | $0 |
| FY Dec 2024 | $0 |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $18.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -346.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$145.3M |
| FY Dec 2023 | -$134.5M |
| FY Dec 2022 | -$127.8M |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$38.1M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$36.6M |
| Sep 2024 | -$34.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-50.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CGEM
| FY Dec 2025 | -44.0% |
| FY Dec 2024 | -32.1% |
| FY Dec 2023 | -31.4% |
| FY Dec 2022 | +23.2% |
| FY Dec 2021 | -21.0% |
| Jun 2026 | -50.3% |
| Mar 2026 | -48.2% |
| Dec 2025 | -44.0% |
| Sep 2025 | -40.2% |
| Jun 2025 | -36.0% |
| Mar 2025 | -36.6% |
| Dec 2024 | -32.1% |
| Sep 2024 | -26.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-46.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CGEM
| FY Dec 2025 | -41.1% |
| FY Dec 2024 | -30.3% |
| FY Dec 2023 | -29.7% |
| FY Dec 2022 | +22.3% |
| FY Dec 2021 | -20.1% |
| Jun 2026 | -46.3% |
| Mar 2026 | -45.0% |
| Dec 2025 | -41.1% |
| Sep 2025 | -38.2% |
| Jun 2025 | -34.4% |
| Mar 2025 | -34.8% |
| Dec 2024 | -30.3% |
| Sep 2024 | -25.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-54.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CGEM
| FY Dec 2025 | -48.2% |
| FY Dec 2024 | -37.6% |
| FY Dec 2023 | -38.4% |
| FY Dec 2022 | +30.0% |
| FY Dec 2021 | -21.7% |
| Jun 2026 | -54.4% |
| Mar 2026 | -52.2% |
| Dec 2025 | -48.2% |
| Sep 2025 | -44.7% |
| Jun 2025 | -40.8% |
| Mar 2025 | -42.6% |
| Dec 2024 | -37.6% |
| Sep 2024 | -34.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 4.43x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | -20.5% |
| FY Dec 2023 | -30.8% |
| FY Dec 2022 | -26.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -49.7% |
| Jun 2025 | -38.6% |
| Mar 2025 | -33.9% |
| Dec 2024 | -20.5% |
| Sep 2024 | -13.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CGEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | $0 |
| Operating income | -$241.6M | -$196.9M | -$191.1M | $144.6M |
| Net income | -$219.9M | -$167.6M | -$155.1M | $111.2M |
| EPS (diluted) | n/a | n/a | -3.69 | 2.38 |
| Operating cash flow | -$175.8M | -$145.3M | -$134.3M | -$126.7M |
| Cash | $88.3M | $83.0M | $98.4M | $156.2M |
SEC XBRL, fiscal years, as known on 2026-10-27
CGEM Stock Sonar score 5/7 axes
Find similar shapesCompareCGEM ranks highest on institutional and government (75th percentile) and profitability (49th), and lowest on growth (1st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CGEM filings, in plain words
Are Cullinan Therapeutics insiders buying or selling CGEM?
In the 180 days to 2026-10-27, Cullinan Therapeutics insiders were net sellers, a net $1.0M across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of CGEM?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $764.7K of stock; the latest, by JENNIFER MICHAELSON, was filed 2026-09-08.
Read the full summary
In the 180 days to 2026-10-27, Cullinan Therapeutics insiders were net sellers of CGEM, a net $1.0M across purchases and sales reported on Form 4 by 1 seller. 20% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $764.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
